Stay updated on Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial
Sign up to get notified when there's something new on the Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial page.

Latest updates to the Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial page
- CheckyesterdayChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check8 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check15 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check23 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check44 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check59 days agoChange DetectedThe page has undergone significant content removal regarding a clinical study on SARS-CoV-2, including details about hyper-inflammation and treatment options, while adding a new revision number and a specific EudraCT number for a study.SummaryDifference25%
Stay in the know with updates to Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial page.